Patients with modest radiologic response to neoadjuvant treatment (NAT) for pancreatic cancer face operative eligibility uncertainties. A novel Sialyl-Lewis Antigen-related Index (SLE Index) combining CA19-9 and Dupan-II reveals significant prognostic value. An SLE Index below 45.25 correlates with favorable disease-free survival, proving superior in predicting recurrence within 24 months compared to individual tumor markers. This index, assessing multiple biologic factors, offers a simplified and effective tool for enhancing patient selection post-NAT.
Journal Article by Miyahara S, Takahashi H (…) Eguchi H et 11 al. in Ann Surg Oncol
© 2024. Society of Surgical Oncology.